Eupraxia Pharmaceuticals Inc.
EPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001581178
No open-market purchases or sales by Eupraxia Pharmaceuticals Inc. insiders were filed in the last 90 days; 67 institutions reported holding it in 13F filings for Q2 2026, worth $163.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +12 vs. previous quarter
- 67
- 13F valueReported value at the end of Q2 2026
- $163.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EPRX, Q2 2026
No superinvestor reported holding EPRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Eupraxia Pharmaceuticals Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Eupraxia Pharmaceuticals Inc. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Eupraxia Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 3,627,864 | $23.8M | 0.18% | −38,601−1.1% | Reduced |
| Affinity Asset Advisors, LLC | 1,650,000 | $10.9M | 0.53% | +60,995+3.8% | Added |
| Balyasny Asset Management LLC | 1,350,015 | $8.92M | 0.02% | +150.0% | Added |
| Vivo Capital, LLC | 1,350,000 | $8.92M | 0.81% | 00.0% | Unchanged |
| Scotia Capital Inc. | 1,343,726 | $8.78M | 0.03% | +1,548+0.1% | Added |
| PFM Health Sciences, LP | 1,210,661 | $8.00M | 0.69% | +669,790+123.8% | Added |
| Great Point Partners LLC | 1,200,000 | $7.93M | 1.87% | 00.0% | Unchanged |
| Jupiter Topco LLC | 1,046,000 | $6.85M | 0.00% | +1,046,000 | New |
| Rubric Capital Management LP | 867,424 | $5.73M | 0.05% | +176,254+25.5% | Added |
| Ikarian Capital, LLC | 809,741 | $5.35M | 0.88% | −405,000−33.3% | Reduced |